
Long-term treatment with abrocitinib, a medication for moderate-to-severe atopic dermatitis (AD), was assessed for patient-reported outcomes. The ongoing JADE EXTEND study included patients from prior abrocitinib trials who received the drug (200 or 100 mg daily) and entered the extension phase. Results showed that baseline quality of life (QoL) was heavily impacted, with scores of 15.4 and 15.3 for abrocitinib 200 and 100 mg groups, respectively. At Week 48, QoL effects were reduced to 4.6 and 5.9 for 200 and 100 mg groups. Patient-reported symptom improvements were substantial, with 44% and 34% achieving better QoL and 90% and 77% experiencing reduced symptom severity with 200 and 100 mg, respectively.
Like
Save
Share